BDNF and early-onset autosomal dominant Alzheimer disease: Specifically, TMS targeting the prefrontal cortex and hippocampal networks improves cholinergic signaling and boosts brain-derived neurotrophic factor (BDNF) levels, as observed in the 3xTgAD mouse model of Alzheimer's disease (98).